RegeneRx to Shift Ophthalmic Clinical Development Strategy

RegeneRx Biopharmaceuticals, Inc. announced that based on encouraging “Compassionate Use” data showing RGN-259’s potential healing effects in patients with non-healing corneal ulcers, the company will close its current double blind, placebo controlled, Phase II clinical trial targeting a small subset of diabetic patients undergoing vitrectomy (DV) surgery in order to focus on a patient population with broader market potential.
The Earth Times